IMVT

Immunovant Inc

IMVT.US immunovant.com
38.10
-0.65 (-1.68%)
USD · NASDAQ
52-week range
14.58
45.42
Trading at 76% of the 52-week range
Market Cap
8.00B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.57
Div. Yield
N/A
% Institutions
54.02%
% Insiders
56.02%

1 Year

+135.2%

3 Year

+69.0%

10 Year

+282.9%
Description

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Company Information

Company Name
Immunovant Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US45258J1025
CIK: 0001764013
CUSIP: 45258J201
Currency: USD
Full Time Employees: 315
Phone: 917 410 3120
Fiscal Year End: March
IPO Date: Jun 21, 2019
Description:

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Address:

1000 Park Forty Plaza, Durham, NC, United States, 27713

People

Directors & Officers

Name Title Year Born
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board 1979
Dr. Eric Venker M.D., Pharm.D. CEO & Director 1987
Mr. Tiago M. Girao CPA Chief Financial Officer 1979
Ms. Melanie Gloria B.S.N. Chief Operating Officer 1978
Dr. Jay S. Stout M.S., Ph.D. Chief Technology Officer 1963
Mr. Christopher A. Van Tuyl Esq., J.D. Chief Legal Officer & Corporate Secretary 1975
Ms. Christine Blodgett Senior Vice President of Human Resources NA
Ms. Becky Merlina Senior VP & Global Head of Quality NA
Ms. Yan Zheng M.S., Ph.D. Senior Vice President of Biostatistics, Programming & Data Management NA
Ms. Sheetal Patel M.B.A., M.D., M.S. Senior Vice President of Clinical Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 23, 2026 Tiago Girao N/A Sale 25.76K $29.62 $763.01K
Apr 23, 2026 Jay S Stout N/A Sale 2.75K $29.62 $81.57K
Apr 08, 2026 Jay S Stout N/A Sale 10.13K $24.83 $251.58K
Apr 08, 2026 Melanie Gloria N/A Sale 8.72K $24.83 $216.57K
Apr 08, 2026 Tuyl Christopher Van N/A Sale 5.17K $24.83 $128.25K
Apr 02, 2026 Eric Venker N/A Sale 14.23K $24.10 $342.92K
Mar 18, 2026 Tuyl Christopher Van N/A Sale 2.88K $24.97 $71.84K
Jan 21, 2026 Jay S Stout N/A Sale 1.98K $26.03 $51.46K
Jan 07, 2026 Jay S Stout N/A Sale 1.20K $26.53 $31.92K
Dec 18, 2025 Tuyl Christopher Van N/A Sale 10.81K $26.91 $290.98K
Dec 01, 2025 Andrew J Fromkin N/A Sale 22.25K $23.25 $517.29K
Dec 01, 2025 Douglas J Hughes N/A Sale 15.00K $23.24 $348.60K
Nov 20, 2025 Melanie Gloria N/A Sale 12.63K $23.62 $298.23K
Oct 22, 2025 Jay S Stout N/A Sale 2.52K $19.03 $47.96K
Oct 22, 2025 Michael Geffner N/A Sale 2.60K $19.03 $49.38K
Oct 08, 2025 Jay S Stout N/A Sale 1.59K $16.30 $25.84K
Oct 08, 2025 Michael Geffner N/A Sale 1.27K $16.30 $20.73K
Jul 23, 2025 Jay S Stout N/A Sale 2.81K $18.15 $50.91K
Jul 23, 2025 Michael Geffner N/A Sale 2.39K $18.15 $43.29K
Jul 09, 2025 Jay S Stout N/A Sale 1.52K $17.24 $26.19K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 16.95M Mar 31, 2026 8.21% $0.02 -0.25%
Deep Track Capital, LP 9.34M Jun 30, 2026 4.52% $5.24 -18.96%
BlackRock Inc 6.57M Mar 31, 2026 3.18% $0.00 8.52%
Baker Bros Advisors LP 5.46M Mar 31, 2026 2.64% $0.78 0.00%
State Street Corp 4.54M Mar 31, 2026 2.20% $0.00 19.83%
TCG Crossover Management, LLC 4.46M Jun 30, 2026 2.16% $4.13 0.00%
Morgan Stanley - Brokerage Accounts 3.88M Mar 31, 2026 1.88% $0.01 -20.00%
Vanguard Portfolio Management, LLC 3.70M Mar 31, 2026 1.79% $0.00 0.00%
Vanguard Capital Management, LLC 3.62M Mar 31, 2026 1.75% $0.00 0.00%
T. Rowe Price Investment Management,Inc. 3.61M Mar 31, 2026 1.75% $0.06 -35.87%
Armistice Capital, LLC 3.56M Mar 31, 2026 1.73% $1.57 -37.97%
Jennison Associates LLC 3.31M Jun 30, 2026 1.60% $0.08 3.55%
Two Seas Capital LP 3.20M Mar 31, 2026 1.55% $1.11 11.68%
RTW INVESTMENTS, LLC 3.18M Mar 31, 2026 1.54% $0.79 0.00%
ADAR1 Capital Management LLC 2.68M Mar 31, 2026 1.30% $3.92 7.98%
Alpine Partners VI, LLC 2.64M Mar 31, 2026 1.28% $9.81 0.39%
Geode Capital Management, LLC 2.09M Mar 31, 2026 1.01% $0.00 12.63%
Woodline Partners LP 1.98M Mar 31, 2026 0.96% $0.19 0.00%
The Goldman Sachs Group Inc 1.79M Mar 31, 2026 0.86% $0.01 37.74%
Perceptive Advisors LLC 1.60M Mar 31, 2026 0.77% $0.78 -19.93%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 6.94M 3.36% ▲ 0.00% Jul 31, 2026
2 Fidelity Growth Company Fund 5.09M 2.47% ▲ 0.00% Jul 31, 2026
3 State Street® SPDR® S&P® Biotech ETF 2.71M 1.31% ▼ 1.06% Aug 31, 2026
4 Vanguard MStar Total Stk Mkt Idx Invest 2.61M 1.26% ▲ 0.44% Jul 31, 2026
5 iShares Russell 2000 ETF 2.17M 1.05% ▼ 0.57% Aug 31, 2026
6 Vanguard Small Cap Index 1.89M 0.91% ▲ 0.25% Jul 31, 2026
7 Fidelity Growth Company K6 1.41M 0.68% ▲ 0.00% Jul 31, 2026
8 Fidelity Series Growth Company 1.10M 0.53% ▲ 0.00% Jul 31, 2026
9 Vanguard MStar Small Cap Growth Indx Inv 1.09M 0.53% ▲ 0.16% Jul 31, 2026
10 T. Rowe Price US Small-Cap Core Equity 991.47K 0.48% ▼ 24.62% Jun 30, 2026

Financial Highlights

Market Cap: $8.00B
EBITDA: $-565.61M
Book Value: $3.57
Earnings/Share: $-2.81
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -46.73%
ROE (TTM): -80.10%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $7.27B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 206.55M
Shares Float: 91.59M
% Insiders: 56.02%
% Institutions: 54.02%
Short % Float: 18.28%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-409.00K
Gross Profit
subtotal
$-409.00K
SG&A
adjust
$-76.24M
R&D
adjust
$-456.66M
Operating Income
subtotal
$-532.90M
Other / Non-Operating Items
adjust
$27.30M
Net Income
subtotal
$-505.61M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMVT.US!